Drug intelligence / Profile preview

GSK3389404

Development stage: Phase 2
Lead developer: GSK
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

GSK3389404 is a liver-targeted antisense oligonucleotide developed for the treatment of chronic hepatitis B (CHB) virus infection. It is the N-acetyl galactosamine (GalNAc)-conjugated version of bepirovirsen (GSK3228836). The drug is designed to inhibit synthesis of hepatitis B surface antigen (HBsAg) and all other hepatitis B virus proteins by targeting a shared region present in all HBV mRNAs and pregenomic RNA. The GalNAc conjugation enhances delivery to hepatocytes. In clinical studies, GSK3389404 demonstrated dose-dependent reductions in HBsAg levels with an acceptable safety profile, though no effective dosing regimen was identified in Phase 2 trials.

Other names: IONIS-HBV-LRxISIS-GSK6-LRxISIS-GSK-6-LRxISIS-GSK 6-LRx

Targets

ASGPR (Asialoglycoprotein Receptor 1)HBV RNA (Hepatitis B virus RNA)

Beyond the preview

Go deeper on GSK3389404.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK3389404.

Explore the full profile